QVAR (beclomethasone dipropionate HFA) Inhalation Aerosol
QVAR

QVAR® Error Page

We're sorry, but you seem to have reached this page in error; the following may have happened to cause this error:
  • - You found this page using a bookmark and the page has moved
  • - This page does not exist anymore
  • - The URL was incorrectly typed into your browser
Please visit the site map or go to the QVAR® home page to find more information about QVAR®.

References
  1. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest. 2002;122:510-516.
  2. Leach CL. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol. 1999;104:S250-S252.
QVAR® is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age or older. QVAR® is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR® may reduce or eliminate the need for systemic corticosteroids.

Important Safety Information


QVAR® does not replace fast-acting (rescue) inhalers for sudden symptoms.

CAUTION: If you are switching from an oral corticosteroid to QVAR®, follow your doctor's instructions to avoid health risks when you stop using oral corticosteroids (See WARNINGS, Prescribing Information).

Inhaled corticosteroids may cause a reduction in growth rate. The long-term effect on final adult growth is unknown.

In clinical studies, common side effects included headache and pharyngitis.

Do not stop taking QVAR® abruptly without talking to your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

110503